IP Library Granted Patent US 8,878,001
Granted Patent B2
US 8,878,001 · App. 13/662,880 · Granted Nov 4, 2014

Humanized IL-6 and IL-6 receptor

Inventors: Li-Hsien Wang (Somers, NY); Anthony T. Dore, Jr. (Mount Vernon, NY); Sean Stevens (San Francisco, CA); Andrew J. Murphy (Croton-on-Hudson, NY)
Assignee: Regeneron Pharmaceuticals, Inc.
A01K67/0278A01K2227/105C07K14/7155A01K2217/072C07K14/5412C07K2319/00A01K2267/03A01K2217/15
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,878,001
App. No.
13/662,880
Granted
Nov 4, 2014
Kind
B2
Abstract

Mice that comprise a replacement of endogenous mouse IL-6 and/or IL-6 receptor genes are described, and methods for making and using the mice. Mice comprising a replacement at an endogenous IL-6Rα locus of mouse ectodomain-encoding sequence with human ectodomain-encoding sequence is provided. Mice comprising a human IL-6 gene under control of mouse IL-6 regulatory elements is also provided, including mice that have a replacement of mouse IL-6-encoding sequence with human IL-6-encoding sequence at an endogenous mouse IL-6 locus.

Claims (4)

1. A genetically modified mouse whose genome comprises a replacement at an endogenous mouse IL-6 locus of a mouse gene encoding IL-6 with a human gene encoding human IL-6, wherein the human gene encoding human IL-6 is under control of endogenous mouse regulatory elements at the endogenous mouse IL-6 locus, and wherein the mouse expresses human IL-6 and the replaced mouse gene encoding IL-6 is not expressed, and wherein the mouse comprises a normal B cell population compared to a wild type mouse.

2. The genetically modified mouse of claim 1 , wherein the mouse expresses a mouse IL-6Rα.

3. The genetically modified mouse of claim 1 , wherein the mouse does not exhibit a feature selected from plasmocytosis, glumerulosclerosis, glomerulonephritis, kidney failure, hypergammaglobulinemia, elevated megakaryocytes in spleen, elevated magakaryocytes in bone marrow, splenomegaly, lymph node enlargement, compacted abnormal plasma cells, and a combination thereof.

4. A method for making a humanized mouse, comprising replacing an endogenous mouse IL-6 locus with a human gene encoding human IL-6 to make a genetically modified mouse whose genome comprises a replacement at an endogenous mouse IL-6 locus of a mouse gene encoding IL-6 with a human gene encoding human IL-6, wherein the human gene encoding human IL-6 is placed under control of endogenous mouse regulatory sequences at the endogenous mouse IL-6 locus and wherein the mouse expresses human IL-6 and the replaced mouse gene encoding IL-6 is not expressed, and wherein the mouse comprises a normal B cell population compared to a wild type mouse.

Assignments (2)
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE ADDRESS PREVIOUSLY RECORDED AT REEL: 031328 FRAME: 0418. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Sep 12, 2014
From: WANG, LI-HSIEN; DORE, ANTHONY T., JR.; STEVENS, SEAN; MURPHY, ANDREW J.
To: REGENERON PHARMACEUTICALS, INC.
Reel/Frame 033727/0287 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 2, 2013
From: WANG, LI-HSIEN; DORE, ANTHONY T., JR.; STEVENS, SEAN; MURPHY, ANDREW J.
To: REGENERON PHARMACEUTICALS, INC.
Reel/Frame 031328/0418 →
Continuity (3)
Provisional Application 61552900 · Oct 28, 2011
Provisional Application 61556579 · Nov 7, 2011
Related Publication 20130117873A1 · May 9, 2013